ROIV
Roivant Sciences Ltd
NASDAQ: ROIV · HEALTHCARE · BIOTECHNOLOGY
$27.52
-0.90% today
Updated 2026-04-29
Market cap
$19.70B
P/E ratio
—
P/S ratio
1,479.80x
EPS (TTM)
$-1.17
Dividend yield
—
52W range
$11 – $30
Volume
5.5M
Roivant Sciences Ltd (ROIV) Insider transactions
Net insider activity
Net selling (26,055,092 shares)
Buy transactions
16
Sell transactions
84
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-16 | GLINE, MATTHEW | Director, CEO | Sale | 289,774 | $29.16 | $8.45M |
| 2026-04-08 | HUMES, JENNIFER | Chief Accounting Officer | Sale | 13,538 | $28.37 | $384073.06 |
| 2026-03-31 | TORTI, FRANK | President and Vant Chair | Sale | 160,035 | $27.70 | $4.43M |
| 2026-03-31 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 187,512 | $27.70 | $5.19M |
| 2026-03-31 | GLINE, MATTHEW | Director, CEO | Sale | 304,684 | $27.70 | $8.44M |
| 2026-03-30 | SUKHATME, MAYUKH | Director, President & CIO | Buy | 58,391 | — | — |
| 2026-03-30 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 29,809 | $26.41 | $787255.69 |
| 2026-03-30 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 1,306,889 | $11.50 | $15.03M |
| 2026-03-30 | GLINE, MATTHEW | Director, CEO | Buy | 97,319 | — | — |
| 2026-03-30 | GLINE, MATTHEW | Director, CEO | Sale | 53,826 | $26.41 | $1.42M |
| 2026-03-30 | GLINE, MATTHEW | Director, CEO | Sale | 2,178,150 | $11.50 | $25.05M |
| 2026-03-26 | FITZGERALD, MEGHAN | Director | Sale | 70,000 | — | — |
| 2026-03-26 | FITZGERALD, MEGHAN | Director | Buy | 70,000 | $8.80 | $616000.00 |
| 2026-03-20 | PULIK, RICHARD | CFO | Sale | 1,546 | $27.70 | $42824.20 |
| 2026-03-20 | HUMES, JENNIFER | Chief Accounting Officer | Sale | 14,526 | $27.70 | $402370.20 |
| 2026-03-17 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | — | — |
| 2026-03-17 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | $28.24 | $5.65M |
| 2026-03-16 | EPPERLY, MELISSA B, | Director | Sale | 41,861 | $28.68 | $1.20M |
| 2026-02-23 | TORTI, FRANK | President and Vant Chair | Sale | 587,390 | — | — |
| 2026-02-23 | TORTI, FRANK | President and Vant Chair | Sale | 587,390 | $27.51 | $16.16M |
| 2026-02-20 | VENKER, ERIC | President & Immunovant CEO | Sale | 7,051 | $27.15 | $191434.65 |
| 2026-02-20 | TORTI, FRANK | President and Vant Chair | Sale | 1,012,610 | — | — |
| 2026-02-20 | TORTI, FRANK | President and Vant Chair | Sale | 1,012,610 | $27.15 | $27.49M |
| 2026-02-20 | PULIK, RICHARD | CFO | Sale | 1,000 | $27.15 | $27150.00 |
| 2026-02-19 | TORTI, FRANK | President and Vant Chair | Sale | 1,400,000 | — | — |
| 2026-02-19 | TORTI, FRANK | President and Vant Chair | Buy | 1,400,000 | $3.85 | $5.39M |
| 2026-02-13 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | — | — |
| 2026-02-13 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | $26.49 | $5.30M |
| 2026-02-13 | QVT, FINANCIAL LP | Director by Deputization | Sale | 225,000 | $26.50 | $5.96M |
| 2026-02-13 | QVT, FINANCIAL LP | Director by Deputization | Sale | 150,784 | $26.49 | $3.99M |
| 2026-02-13 | MANCHESTER, KEITH S | Director | Sale | 225,000 | $26.50 | $5.96M |
| 2026-02-13 | MANCHESTER, KEITH S | Director | Sale | 150,784 | $26.49 | $3.99M |
| 2026-02-13 | GOLD, DANIEL ALLEN | Director | Sale | 225,000 | $26.50 | $5.96M |
| 2026-02-13 | GOLD, DANIEL ALLEN | Director | Sale | 150,784 | $26.49 | $3.99M |
| 2026-02-12 | QVT, FINANCIAL LP | Director by Deputization | Sale | 275,000 | $26.76 | $7.36M |
| 2026-02-12 | QVT, FINANCIAL LP | Director by Deputization | Sale | 150,000 | $26.72 | $4.01M |
| 2026-02-12 | MANCHESTER, KEITH S | Director | Sale | 275,000 | $26.76 | $7.36M |
| 2026-02-12 | MANCHESTER, KEITH S | Director | Sale | 150,000 | $26.72 | $4.01M |
| 2026-02-12 | GOLD, DANIEL ALLEN | Director | Sale | 275,000 | $26.76 | $7.36M |
| 2026-02-12 | GOLD, DANIEL ALLEN | Director | Sale | 150,000 | $26.72 | $4.01M |
| 2026-02-11 | QVT, FINANCIAL LP | Director by Deputization | Sale | 425,000 | $26.67 | $11.33M |
| 2026-02-11 | MANCHESTER, KEITH S | Director | Sale | 425,000 | $26.67 | $11.33M |
| 2026-02-11 | GOLD, DANIEL ALLEN | Director | Sale | 425,000 | $26.67 | $11.33M |
| 2026-02-09 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 651,558 | — | — |
| 2026-02-09 | SUKHATME, MAYUKH | Director, President & CIO | Buy | 651,558 | $12.68 | $8.26M |
| 2026-02-09 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 339,441 | $26.47 | $8.99M |
| 2026-02-09 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 312,117 | $26.47 | $8.26M |
| 2026-01-20 | OREN, ILAN | Director | Buy | 1,164 | — | — |
| 2026-01-20 | OREN, ILAN | Director | Sale | 124 | $22.98 | $2849.52 |
| 2026-01-20 | MOMTAZEE, JAMES C | Director | Buy | 609 | — | — |
| 2026-01-20 | MOMTAZEE, JAMES C | Director | Sale | 122 | $22.98 | $2803.56 |
| 2026-01-20 | EPPERLY, MELISSA B, | Director | Buy | 815 | — | — |
| 2026-01-20 | EPPERLY, MELISSA B, | Director | Sale | 54 | $22.98 | $1240.92 |
| 2026-01-12 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | — | — |
| 2026-01-12 | VENKER, ERIC | President & Immunovant CEO | Buy | 200,000 | $3.85 | $770000.00 |
| 2025-12-31 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 2,449,877 | — | — |
| 2025-12-31 | SUKHATME, MAYUKH | Director, President & CIO | Buy | 2,449,877 | $12.68 | $31.06M |
| 2025-12-31 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 1,430,882 | $21.71 | $31.06M |
| 2025-12-31 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 1,018,995 | $21.71 | $22.12M |
| 2025-12-29 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 748,358 | — | — |
| 2025-12-29 | SUKHATME, MAYUKH | Director, President & CIO | Buy | 748,358 | $12.68 | $9.49M |
| 2025-12-29 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 436,485 | $21.74 | $9.49M |
| 2025-12-29 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 311,873 | $21.74 | $6.78M |
| 2025-12-24 | VENKER, ERIC | President & Immunovant CEO | Sale | 117,848 | — | — |
| 2025-12-24 | VENKER, ERIC | President & Immunovant CEO | Buy | 117,848 | $3.85 | $453714.80 |
| 2025-12-24 | VENKER, ERIC | President & Immunovant CEO | Sale | 75,000 | $22.53 | $1.69M |
| 2025-12-24 | TORTI, FRANK | President and Vant Chair | Sale | 110,489 | — | — |
| 2025-12-24 | TORTI, FRANK | President and Vant Chair | Sale | 64,891 | $22.47 | $1.46M |
| 2025-12-23 | VENKER, ERIC | President & Immunovant CEO | Sale | 313,841 | — | — |
| 2025-12-23 | VENKER, ERIC | President & Immunovant CEO | Buy | 313,841 | $3.85 | $1.21M |
| 2025-12-23 | VENKER, ERIC | President & Immunovant CEO | Sale | 200,000 | $22.45 | $4.49M |
| 2025-12-23 | TORTI, FRANK | President and Vant Chair | Buy | 175,380 | $22.45 | $3.94M |
| 2025-12-23 | PULIK, RICHARD | CFO | Sale | 260,000 | — | — |
| 2025-12-23 | PULIK, RICHARD | CFO | Buy | 260,000 | $3.85 | $1.00M |
| 2025-12-23 | PULIK, RICHARD | CFO | Sale | 146,731 | $22.39 | $3.29M |
| 2025-12-20 | PULIK, RICHARD | CFO | Sale | 2,129 | $22.41 | $47710.89 |
| 2025-12-17 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 59,513 | — | — |
| 2025-12-17 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 32,682 | $23.09 | $754627.38 |
| 2025-12-17 | SUKHATME, MAYUKH | Director, President & CIO | Sale | 26,831 | $23.09 | $619527.79 |
| 2025-12-17 | QVT, FINANCIAL LP | Director by Deputization | Sale | 432,718 | $23.05 | $9.97M |
| 2025-12-17 | QVT, FINANCIAL LP | Director by Deputization | Sale | 189,538 | $23.17 | $4.39M |
| 2025-12-17 | QVT, FINANCIAL LP | Director by Deputization | Sale | 155,076 | $23.02 | $3.57M |
| 2025-12-17 | MANCHESTER, KEITH S | Director | Sale | 432,718 | $23.05 | $9.97M |
| 2025-12-17 | MANCHESTER, KEITH S | Director | Sale | 189,538 | $23.17 | $4.39M |
| 2025-12-17 | MANCHESTER, KEITH S | Director | Sale | 155,076 | $23.02 | $3.57M |
| 2025-12-17 | GOLD, DANIEL ALLEN | Director | Sale | 432,718 | $23.05 | $9.97M |
| 2025-12-17 | GOLD, DANIEL ALLEN | Director | Sale | 189,538 | $23.17 | $4.39M |
| 2025-12-17 | GOLD, DANIEL ALLEN | Director | Sale | 155,076 | $23.02 | $3.57M |
| 2025-12-16 | QVT, FINANCIAL LP | Director by Deputization | Sale | 642,282 | $23.08 | $14.82M |
| 2025-12-16 | QVT, FINANCIAL LP | Director by Deputization | Sale | 275,000 | $22.93 | $6.31M |
| 2025-12-16 | MANCHESTER, KEITH S | Director | Sale | 642,282 | $23.08 | $14.82M |
| 2025-12-16 | MANCHESTER, KEITH S | Director | Sale | 275,000 | $22.93 | $6.31M |
| 2025-12-16 | GOLD, DANIEL ALLEN | Director | Sale | 642,282 | $23.08 | $14.82M |
| 2025-12-16 | GOLD, DANIEL ALLEN | Director | Sale | 275,000 | $22.93 | $6.31M |
| 2025-12-15 | RAMASWAMY, VIVEK | 10% Owner | Sale | 832,453 | — | — |
| 2025-12-15 | RAMASWAMY, VIVEK | 10% Owner | Buy | 832,453 | $12.68 | $10.56M |
| 2025-12-15 | RAMASWAMY, VIVEK | 10% Owner | Sale | 478,708 | $22.05 | $10.56M |
| 2025-12-15 | RAMASWAMY, VIVEK | 10% Owner | Sale | 353,745 | $22.05 | $7.80M |
| 2025-12-15 | GLINE, MATTHEW | Director, CEO | Sale | 2,272,852 | — | — |
| 2025-12-15 | GLINE, MATTHEW | Director, CEO | Sale | 1,363,711 | — | — |